Sugi Predict

Sugi Predict / Compounds / SCHEMBL1780239

SCHEMBL1780239

SCHEMBL1780239

Cn1nc(C=O)cc1-c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 2/20 0.43
▸ CRBN Q96SW2 2/20 0.43
▸ GRM5 P41594 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.40
▸ RAB9A P51151 3/20 0.39
▸ KDM4E B2RXH2 3/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ HPGD P15428 2/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ BRD4 O60885 1/20 0.37
▸ KDM4C Q9H3R0 1/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ NR1H2 P55055 1/20 0.37
▸ NR1H3 Q13133 1/20 0.37
▸ CCNB2 O95067 1/20 0.37
▸ CDK1 P06493 1/20 0.37
▸ CCNB1 P14635 1/20 0.37
▸ CDK5 Q00535 1/20 0.37
▸ CDK5R1 Q15078 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3953715 0.83 HDAC6 (0.42) ALDH1A1RAB9AKDM4ESMN1; SMN2NPC1
SCHEMBL20430767 0.83 PTGS2 (0.39) RAB9ANPC1KMT2APTGS2
SCHEMBL19259595 0.83 NOTUM (0.41) ALDH1A1KDM4ESMN1; SMN2HPGDHSD17B10
SCHEMBL3954814 0.82 DYRK1A (0.39) ALDH1A1KDM4EHSD17B10KDM4CCYP1A2
SCHEMBL14293370 0.82 GRM5 (0.41) DDB1CRBNGRM5ALDH1A1RAB9A
SCHEMBL17259215 0.78 P2RY6 (0.47) ALDH1A1RAB9AKDM4ESMN1; SMN2NPC1
SCHEMBL5385383 0.78 NMT1 (0.39) ALDH1A1KDM4ESMN1; SMN2CDK5CDK5R1
SCHEMBL4245811 0.77 NPC1 (0.57) ALDH1A1RAB9ANPC1HPGDKMT2A
SCHEMBL5389341 0.75 FYN (0.39) —
SCHEMBL27517748 0.75 DDB1 (0.41) DDB1CRBNGRM5ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570626-B2 Degraders and degrons for targeted protein degradation C4 THERAPEUTICS, INC. (US) 2026-03-10 — — US disclosed
CN-112533964-B Bidentate azolylaminomethyl-ligand complexes and olefin polymerization catalysts 陶氏环球技术有限责任公司 2024-03-12 — — CN disclosed
US-20230357180-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-11-09 — — US disclosed
US-20230357180-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-11-09 — — US disclosed
US-20230357180-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-11-09 — — US disclosed
US-11708429-B2 Bidentate azolylamido metal-ligand complexes and olefin polymerization catalysts DOW GLOBAL TECHNOLOGIES LLC (US) 2023-07-25 — — US disclosed
US-11708429-B2 Bidentate azolylamido metal-ligand complexes and olefin polymerization catalysts DOW GLOBAL TECHNOLOGIES LLC (US) 2023-07-25 — — US disclosed
US-11708429-B2 Bidentate azolylamido metal-ligand complexes and olefin polymerization catalysts DOW GLOBAL TECHNOLOGIES LLC (US) 2023-07-25 — — US disclosed
US-11524949-B2 Degraders and Degrons for targeted protein degradation C4 THERAPEUTICS, INC. (US) 2022-12-13 — — US disclosed
US-11524949-B2 Degraders and Degrons for targeted protein degradation C4 THERAPEUTICS, INC. (US) 2022-12-13 — — US disclosed
US-20040198737-A1 Azaindoles AVENTIS PHARMA LIMITED (GB) 2004-10-07 — — US disclosed
US-6770643-B2 Azaindoles AVENTIS PHARMA LIMITED (GB) 2004-08-03 — — US disclosed
US-20040053931-A1 Azaindoles AVENTIS PHARMACEUTICALS INC. 2004-03-18 — — US disclosed
EP-1397360-A1 AZAINDOLES Aventis Pharma Limited (GB) 2004-03-17 — — EP disclosed
US-20040009983-A1 Azaindoles AVENTIS PHARMA LIMITED (GB) 2004-01-15 — — US disclosed
CN-1413213-A Azaindoles AVENTIS PHARMA LTD (GB) 2003-04-23 — — CN disclosed
WO-2003000688-A1 AZAINDOLES AVENTIS PHARMA LIMITED (GB) 2003-01-03 — — WO disclosed
EP-1263759-A2 AZAINDOLES Aventis Pharma Limited (GB) 2002-12-11 — — EP disclosed
WO-2001047922-A2 AZAINDOLES AVENTIS PHARMA LIMITED (GB) 2001-07-05 — — WO disclosed
CN-1289326-A N-[(substituted five-membered di-or thiaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia PFIZER PROD INC (US) 2001-03-28 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198737-A1 Azaindoles CCNY, CCNO, CNKSR1 DDB1 2222/4885CRBN 234/4885GRM5 3493/4885
US-20040053931-A1 Azaindoles CDKN1A, CDK7, CDK2 DDB1 2844/4885CRBN 2564/4885GRM5 1609/4885
US-11708429-B2 Bidentate azolylamido metal-ligand complexes and olefin polymerization catalysts LIG4, PARG, PIN1 DDB1 695/4885CRBN 474/4885GRM5 2810/4885
US-12570626-B2 Degraders and degrons for targeted protein degradation ADRM1, UCHL3, USP30 DDB1 1105/4885CRBN 25/4885GRM5 4573/4885
US-20040009983-A1 Azaindoles CCNY, CCNO, CKS2 DDB1 2450/4885CRBN 240/4885GRM5 3419/4885
US-20230357180-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION STUB1, MDM2, USP30 DDB1 292/4885CRBN 37/4885GRM5 4578/4885
US-11524949-B2 Degraders and Degrons for targeted protein degradation STUB1, MDM2, USP30 DDB1 292/4885CRBN 37/4885GRM5 4578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.